90002-56-5

Basic information

• Product Name: N-(2-AMINOETHYL) 4-BROMOBENZENESULFONAMIDE
• Synonyms: N-(2-AMINOETHYL) 4-BROMOBENZENESULFONAMIDE;N-(2-AMINOETHYL)-4-BROMOBENZENESULPHONAMIDE;N-(2-Aminoethyl)-4-bromobenzenesulphonamide 96%;N-(2-Aminoethyl)-4-bromobenzenesulphonamide96%
• CAS NO: 90002-56-5
• Molecular Formula: C₈H₁₁BrN₂O₂S
• Molecular Weight: 279.15
• Product Categories: blocks;Bromides;Sulfonamides
• Mol File: 90002-56-5.mol
• Article Data: 7

Chemical Properties

• Melting Point: 112-114
• Boiling Point: 394.9 °C at 760 mmHg
• Flash Point: 192.6 °C
• Appearance: /
• Density: 1.582 g/cm³
• Vapor Pressure: 1.91E-06mmHg at 25°C
• Storage Temp.: 2-8°C
• PKA: 11.18±0.10(Predicted)
• CAS DataBase Reference: N-(2-AMINOETHYL) 4-BROMOBENZENESULFONAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-AMINOETHYL) 4-BROMOBENZENESULFONAMIDE(90002-56-5)
• EPA Substance Registry System: N-(2-AMINOETHYL) 4-BROMOBENZENESULFONAMIDE(90002-56-5)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 90002-56-5(Hazardous Substances Data)

Usage

General Description

"N-(2-aminoethyl) 4-bromobenzenesulfonamide" is a chemical compound with the molecular formula C8H10BrNO2S. It is a derivative of sulfonamide, commonly used as a pharmaceutical intermediate in the synthesis of various medications. N-(2-AMINOETHYL) 4-BROMOBENZENESULFONAMIDE contains a bromo substituent on the benzene ring, making it useful in the development of drugs targeting specific biological pathways. The aminoethyl group also allows for the formation of potential hydrogen bonds with other molecules, enhancing its pharmaceutical properties. "N-(2-aminoethyl) 4-bromobenzenesulfonamide" has the potential to be a key building block in the development of new drugs for various medical conditions.

InChI:InChI=1/C8H11BrN2O2S/c9-7-1-3-8(4-2-7)14(12,13)11-6-5-10/h1-4,11H,5-6,10H2/p+1

Upstream product

• 2576-47-8 2-bromoethylamine hydrobromide 
• 98-58-8 4-bromobenzenesulfonyl chloride 
• 107-15-3 ethylenediamine 

Relevant articles and documents

Anticancer profile and anti-inflammatory effect of new N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide derivatives

A new series of N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide derivatives 11a-o were designed and synthesized based on our previous works. The new series was tested for its anticancer and anti-inflammatory effects. The anticancer profile of

Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking

B-Raf mutation was identified as a key target in cancer treatment. Based on structural features of dabrafenib (potent FDA approved B-Raf inhibitor), the design of new NH2-based imidazothiazole derivatives was carried out affording new highly potent derivatives of imidazothiazole-based scaffold with amino substitution on the terminal phenyl ring as well as side chain with sulfonamide group and terminal substituted phenyl ring. In vitro enzyme assay was investigated against V600E B-Raf kinase. Compounds 10l, 10n and 10o showed higher inhibitory activities (IC50 = 1.20, 4.31 and 6.21 nM, respectively). In vitro cytotoxicity evaluation was assessed against NCI-60 cell lines. Most of tested derivatives showed cytotoxic activities against melanoma cell line. Compound 10k exhibited most potent activity (IC50 = 2.68 μM). Molecular docking study revealed that the new designed derivatives preserved the same binding mode of dabrafenib with V600E B-Raf active site. It was investigated that the new modification in the synthesized derivatives (substituted with NH2) had a significant inhibitory activity towards V600E B-Raf. This core scaffold is considered a key compound for further structural and molecular optimization.

Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold

In this work, a new series of imidazo[2,1-b]thiazole was designed and synthesized. The new compounds are having 3-fluorophenyl at position 6 of imidazo[2,1-b]thiazole and pyrimidine ring at position 5. The pyrimidine ring containing either amide or sulphonamide moiety attached to a linker (ethyl or propyl) at position 2 of the pyrimidine ring. The final compounds were selected by NCI for in vitro cytotoxicity screening. Most derivatives showed cytotoxic activity against colon cancer and melanoma cell lines. In addition, IC50s of the target compounds were determined over A375 and SK-MEL-28 cell lines using sorafenib as positive control. Compounds12b, 12c, 12e, 12f, 15a, 15d, 15f, 14g and 15h exhibited superior activity when compared to sorafenib. The most potent compounds were tested against wild type BRAF, v600e BRAF, and CRAF. Compound 15h exhibited a potential inhibitory effect againstV600EBRAF (IC50 = 9.3 nM).